BioCentury
ARTICLE | Clinical News

ABBV-974: Phase II started

March 28, 2016 7:00 AM UTC

Galapagos began the open-label, international Phase II SAPHIRA 1 trial to evaluate 3 doses of oral GLPG1837 twice daily for 4 weeks in >=12 patients with the G551D mutation. Last month, the company be...